RxDoctor Payments Data

David Young, DO

Pulmonary Disease · Wyomissing, PANPI 1285954321

Payments from drug & device makers

$12,345in general payments, 2019–2025

Across 201 payments — averaging $61.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$4K
  • Intuitive Surgical$4K
  • GSK$701
  • AstraZeneca$505
  • Sanofi$350
  • Regeneron Healthcare Solutions, Inc.$324
  • plus $2K from 31 others

What the payments were for

  • Travel & lodging$96111%
  • Food & beverage$4,39953%
  • Education$3,00036%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,345 in reported general payments places this provider in the 75th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$292,440
Medicare patients
677
Services billed
3,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate19$245,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter195$223,126
EsbrietPirfenidone11$114,062
Breo ElliptaFluticasone/Vilanterol130$80,901
Stiolto RespimatTiotropium Br/Olodaterol Hcl64$50,589
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr61$49,140
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$43,617
Spiriva RespimatTiotropium Bromide33$32,780
SymbicortBudesonide/Formoterol Fumarate57$21,106
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$16,477
Advair HfaFluticasone Propion/Salmeterol27$12,359
Albuterol Sulfate HfaAlbuterol Sulfate206$6,588
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$6,407
Incruse ElliptaUmeclidinium Bromide16$6,325
Varenicline Tartrate35$6,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$701$359,492402 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$133$329,249116 claims
Genentech USA, Inc.Esbriet$55$114,06211 claims
AstraZenecaBreztri Aerosphere, Symbicort$505$64,722102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →